Back to results
US 2019/0100492 A1Published application
Treatment for lipodystrophy
AssigneeCadila Healthcare Limited
InventorsDhiraj Gambhire, Rajendrakumar Hariprasad Jani, Bipin Pandey, Kaushik Sata, Himanshu Kothari, Pankaj Ramanbhai Patel
Life of this patent
Estimating the term…
Abstract
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
Claims16
1-32. (canceled)
A pharmaceutical composition comprising:
- a compound of formula (I)
- wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg;
- and
- a pharmaceutically acceptable excipient.
1 more element
A pharmaceutical composition comprising:
- a) a compound of formula (I)
- wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg;
- b) a buffering agent;
- c) a stabilizer;
- d) optionally a second therapeutic agent;
- and
- e) optionally one or more pharmaceutically acceptable excipients.
4 more elements
A pharmaceutical composition comprising:
- i) a compound of formula (I)
- wherein the compound of formula (I) is present in an amount between about 1 mg to about 500 mg;
- and
- ii) a second therapeutic agent,
- wherein the second therapeutic agent is selected from the group consisting of an agent used to control blood glucose levels, an agent used to control lipid levels, an antioxidant, an appetite suppressing agent, an anti-obesity agent, an antibiotic, a probiotic, and an anti-inflammatory agent.
2 more elements
Dependencies are inferred from the claim text.